[Editor Note: This section is applicable to all applications with a filing date, or, for national phase applications, an international filing date, on or after July 1, 2022, having disclosure of one or more nucleotide and/or amino acid sequences as defined in 37 CFR 1.831(b).]

37 C.F.R. 1.831 Requirements for patent applications filed on or after July 1, 2022, having nucleotide and/or amino acid sequence disclosures.

1. *****

2. (d) "Enumeration of its residues" means disclosure of a nucleotide or amino acid sequence in a patent application by listing, in order, each residue of the sequence, where the residues are represented in the manner as defined in paragraph 3(c)(i) or (ii) of WIPO Standard ST.26 (incorporated by reference, see § 1.839 ).

3. *****

WIPO Standard ST.26 specifies that "enumeration of its residues" means "disclosure of a sequence in a patent application by listing, in order, each residue of the sequence, wherein either (i) the residue is represented by a name, abbreviation, symbol, or structure (e.g., HHHHHHQ or HisHisHisHisHisHisGln); or (ii) multiple residues are represented by a shorthand formula (e.g., His6Gln) (WIPO Standard ST.26, paragraph 3(c)). See also the Guidance portion of the Standard, Annex VI, page 3.26.vi.2 for a discussion of "enumeration of its residues" and page 3.26.vi.18-19, 51, 53 for examples.